QR Pharma Announces Testing of Posiphen in
Mild to Moderate Alzheimer's patients
Study to Evaluate Safety, Mechanism of Action and Efficacy of Posiphen

June 2, 2016, QR Pharma, Inc. (QR), Berwyn, PA: QR a clinical-stage specialty pharmaceutical company committed to developing therapeutics for the treatment of Alzheimer and Parkinson's disease announced today, together with the Alzheimer's Disease Cooperative Study at the University of California, San Diego, that it is initiating a clinical trial to test the effects of Posiphen, the Company's lead compound, on neurotoxic, aggregating proteins in human spinal fluid by stable isotope labeling kinetics (SILK).

William Mobley, MD, Ph.D., Chair of the Department of Neurosciences at the University of California San Diego (UCSD), and Martin Farlow, MD, Professor and Vice Chairman of Research**,** Indiana University School of Medicine are serving as Project Directors for the study. "We are looking forward to using innovative technology to study the effect of Posiphen on amyloid metabolism in the spinal fluid of patients with early stage Alzheimer's disease," commented Dr. Farlow. "Amyloid is the protein that composes plaques in Alzheimer's disease."

The ADCS is coordinating the trial under the direction of Howard Feldman, MD, FACP, UCSD's newly appointed Dean for Alzheimer's and Related Neurodegenerative Research. "We are delighted with the opportunity to work with QR Pharma and to advance the development of pharmacodynamic biomarkers towards proof of concept in a multi-site setting." Funding for this research came through the National Institute on Aging ADCS grant.

This study is breaking new ground in the Alzheimer's field. It combines state-of-the-art stable isotope labeling kinetics (SILK) to evaluate the effects of Posiphen on neurotoxic aggregating proteins in spinal fluid with safety, pharmacokinetics, pharmacodynamics and efficacy.

"We are extremely pleased that Posiphen was chosen by the ADCS for this study," said Maria Maccecchini, Ph.D., CEO of QR Pharma. "It will provide proof of mechanism and proof of concept for Posiphen. It will also provide the necessary dose range and safety information we need to progress our drug development into pivotal phase II/III clinical efficacy studies."

About ADCS: The **Alzheimer's Disease Cooperative Study (ADCS)** was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego. The ADCS s is part of the NIA Division of Neuroscience program's effort to facilitate the discovery, development and testing of new drugs for the treatment of AD.

About Posiphen®: QR's lead compound, Posiphen, is a small orally active compound with high blood brain barrier permeability. It has been shown in cell cultures and in a number of mice models to reduce and normalize the synthesis of amyloid-β precursor

protein (APP) and Aβ, tau and phospho-tau as well as alpha-synuclein; proteins that are all elevated in the injured brain and that have all been shown to kill nerve cells. Since these neurotoxic proteins cause inflammation in the brain, lowering their levels reduces inflammatory factors and inflammation.

For more information on QR Pharma, please visit the company's website, www.qrpharma.com

Contact Maria Maccecchini, PhD
Tel: 610-727 3710
Fax: 610 727 4001

maccecchini@qrpharma.com
www.qrpharma.com